SIBO: Small Intestinal Bacterial Overgrowth¶

SIBO (Small Intestinal Bacterial Overgrowth) is a condition where bacteria colonize the small intestine in abnormally high numbers. It is increasingly recognized as the leading candidate diagnosis for [[lynn-profile|Lynn's]] digestive insufficiency symptoms, and it creates a direct mechanistic link between digestive enzyme deficit and gout inflammation through NLRP3 inflammasome activation.

Connection to Lynn's Digestive Insufficiency¶

Lynn presents with: - Bloating after meals - Gas and abdominal discomfort - Feeling overly full quickly - Occasional loose stools - Fatigue after eating - Gradual nutrient deficiencies (hair thinning, brittle nails)

Current leading diagnosis: SIBO — based on the pattern of symptoms, the response to broad-spectrum enzyme supplementation (BoulderBio), and the clinical recognition that SIBO is underdiagnosed as a cause of these non-specific digestive complaints.

(Source: enzyme-deficit-deep-dive.md) — "SIBO (Small Intestinal Bacterial Overgrowth): Bacteria in the small intestine that shouldn't be there compete for nutrients and produce inflammatory byproducts that damage the mucosal lining. SIBO is a common driver of enzyme insufficiency that often gets overlooked in favor of simpler explanations. Update: SIBO is now the leading candidate diagnosis for Lynn's digestive symptoms — it explains the bloating, the pattern of food intolerances, and why broad-spectrum enzyme supplementation helps (it compensates for the brush-border damage) without fully resolving the underlying issue."

The Brush-Border Damage Mechanism¶

Normal Brush-Border Enzymes¶

The small intestine's epithelial cells express brush-border enzymes — enzymes physically embedded in the microvilli that line the intestinal wall:

Lactase: Breaks down lactose
Sucrase, maltase: Break down disaccharides
DPP-IV: Breaks down proline-rich peptides (including gluten fragments)
Peptidases: Break down small peptides

These enzymes work "on the cell surface," digesting the final breakdown products of food before they're absorbed.

SIBO-Induced Damage¶

When bacteria overgrow in the small intestine, they:

Damage intestinal villi directly — triggering inflammation and blunting the microvilli where brush-border enzymes are anchored
Produce inflammatory byproducts — bacterial metabolites and lipopolysaccharides (LPS) trigger mucosal inflammation
Reduce enzyme surface area — blunted or inflamed villi means fewer enzymes are available for food breakdown
Compete for nutrients — bacteria consume amino acids, vitamins, and other nutrients before the host can absorb them

(Source: enzyme-deficit-deep-dive.md) — "Gut inflammation: Crohn's disease, ulcerative colitis, and even chronic low-grade inflammation from food sensitivities can damage the brush-border enzymes. These are physically embedded in the intestinal villi — if the villi are inflamed or blunted, you lose enzyme surface area."

SIBO and NLRP3: The Shared Inflammatory Pathway¶

The connection to Brian's gout emerges here: SIBO drives NLRP3 inflammasome activation in gut epithelial cells and immune cells.

The mechanism:

Bacterial LPS (lipopolysaccharide) from gram-negative bacteria in SIBO enters the lamina propria
LPS activates TLR4 on macrophages and gut epithelial cells
TLR4 signaling primes NF-κB (Signal 1 of NLRP3 inflammasome)
Additional inflammatory signals from SIBO trigger NLRP3 assembly (Signal 2)
Result: Enhanced IL-1β production in the gut

This means SIBO creates a chronically inflamed intestinal environment with elevated NLRP3 activation — the same pathway that drives Brian's gout flares, just in a different tissue.

(Source: peptide-gout-addendum.md) — "The same NLRP3 inflammasome pathway that drives gout flares is a central driver of intestinal inflammation — including the chronic low-grade inflammation associated with SIBO. This creates a direct connection to Lynn's digestive situation (see The Enzyme Deficit Connection): SIBO damages the brush-border enzymes, worsens enzyme insufficiency, and drives the same inflammatory pathways that KPV targets."

Diagnosis: Breath Testing¶

The SIBO Breath Test¶

SIBO is diagnosed using a breath test (hydrogen/methane): - Patient ingests lactulose or glucose (substrate for bacterial fermentation) - Bacteria in the small intestine ferment the substrate, producing hydrogen and/or methane - Patient's breath is measured for these gases at intervals - Abnormally early rise in H₂/CH₄ indicates bacterial fermentation in the small intestine (vs. normal colonic fermentation)

(Source: enzyme-deficit-deep-dive.md) — "A breath test can confirm this, and treatment with rifaximin typically produces significant improvement."

Clinical Correlation¶

The breath test should be paired with: - Symptom history consistent with SIBO (bloating after meals, gas, loose stools) - Response to probiotics or antimicrobial treatment - Exclusion of other causes (celiac disease, IBS-D, etc.)

Treatment Approaches¶

Pharmaceutical: Rifaximin¶

Rifaximin is a non-absorbed oral antibiotic specifically FDA-approved for SIBO (and traveler's diarrhea). It selectively targets gram-negative bacteria in the small intestine without systemic absorption.

Typical dosing: 550 mg three times daily for 14 days
Efficacy: ~70% of patients see symptom improvement
Relapse: ~40% of treated patients relapse within 12 months

(Source: enzyme-deficit-deep-dive.md) — "Treatment with rifaximin typically produces significant improvement."

Herbal / Natural: Berberine¶

Berberine deserves specific mention because it addresses BOTH Lynn's SIBO and Brian's gout through shared NLRP3 suppression:

Berberine: - Kills small-intestinal bacteria (comparable efficacy to rifaximin in head-to-head trials) - Suppresses NF-κB (Signal 1 of NLRP3) - Reduces NLRP3/ASC/caspase-1 expression - Remodels gut microbiota to reduce LPS-producing gram-negatives

(Source: nlrp3-exploit-map.md) — "Berberine is a triple threat: it directly inhibits NF-κB, it dose-dependently suppresses NLRP3/ASC/caspase-1/IL-1β at the mRNA level, and it remodels the gut microbiota to reduce the LPS (lipopolysaccharide) that primes NLRP3 in the first place... The SIBO connection: Berberine is being studied head-to-head against rifaximin for SIBO eradication. Clinical trials suggest comparable efficacy. If Lynn has SIBO, berberine addresses her gut dysbiosis while simultaneously suppressing your NLRP3 cascade. Same compound, both conditions."

Enzyme Supplementation (Symptomatic Management)¶

Until SIBO is eradicated, enzyme supplementation (like BoulderBio) compensates for brush-border damage by providing external enzymes that do the work the damaged villi cannot:

Protease (acid-stable + alkaline) replaces damaged proteases
Lipase replaces damaged lipase
Amylase replaces damaged amylase

This is why Lynn sees symptom improvement on enzyme supplements — they bypass the damaged brush-border enzymes. However, supplementation does not treat the underlying SIBO.

(Source: enzyme-deficit-deep-dive.md) — "Enzyme supplements aren't magic. They can't fix the underlying cause of insufficiency. They don't address gut inflammation, SIBO, or biliary problems... But for genuine enzyme insufficiency — where the right enzymes simply aren't present in adequate quantities — supplementation works, and it works reliably."

KPV and SIBO: Mechanistic Connection¶

[[kpv-peptide|KPV]] peptide has particular relevance here because:

Direct gut anti-inflammatory action: KPV reduces intestinal NLRP3 activation
Brush-border support: By reducing inflammation, KPV may help damaged brush-border enzymes recover
Dual benefit: Addresses both Lynn's gut inflammation (SIBO-driven) and Brian's systemic NLRP3 activation (gout-driven)

(Source: peptide-gout-addendum.md) — "KPV's gut anti-inflammatory properties are especially relevant beyond gout. The same NLRP3 inflammasome pathway that drives gout flares is a central driver of intestinal inflammation — including the chronic low-grade inflammation associated with SIBO."

A theoretical protocol combining rifaximin (SIBO eradication) + KPV (intestinal NLRP3 suppression) + enzyme supplements (symptom management) addresses all three dimensions of Lynn's problem.

Practical Pathway Forward for Lynn¶

Confirm diagnosis: Hydrogen/methane breath test for SIBO
Primary treatment: Rifaximin (14-day course) or berberine protocol
Support healing: KPV peptide (oral, for gut-specific anti-inflammatory effects)
Symptom management: Continue enzyme supplementation during and after SIBO treatment
Prevention: Maintain healthy diet, consider prokinetic support (low-dose domperidone, metoclopramide) if SIBO recurs

Shared Inflammatory Pathway: Brian & Lynn¶

The profound insight: Brian and Lynn are experiencing the same NLRP3-driven inflammation in different tissues.

Brian: MSU crystals → macrophage phagocytosis → NLRP3 activation in joint tissue → IL-1β → pain
Lynn: SIBO bacteria → LPS production → TLR4 signaling → NLRP3 activation in gut epithelium → brush-border damage → enzyme insufficiency

Both conditions represent pathological NLRP3 inflammasome activation. Treatments targeting NLRP3 ([[bhb-ketones|BHB]], [[kpv-peptide|KPV]], [[oridonin|oridonin]], [[berberine|berberine]]) could theoretically benefit both.

(Source: nlrp3-exploit-map.md) — "Bottom line: build ONE stack, share it. Most of these compounds are household-level interventions that benefit both conditions through the shared NLRP3 mechanism."

[[enzyme-deficit|Enzyme Deficit and Digestive Insufficiency]] — The broader context
[[digestive-enzymes|Digestive Enzymes and Supplementation]] — The compensatory strategy
[[nlrp3-inflammasome|NLRP3 Inflammasome]] — The shared inflammatory pathway
[[kpv-peptide|KPV Tripeptide]] — Relevant therapeutic compound
[[lynn-profile|Lynn's Health Profile]] — Personal context
[[berberine|Berberine]] — Dual-benefit SIBO treatment

Key Insight¶

SIBO is not just Lynn's GI problem — it's a driver of systemic NLRP3 inflammasome activation that creates a mechanistic bridge to Brian's gout. By treating SIBO (and supporting gut healing with KPV or other NLRP3 inhibitors), both the direct intestinal damage and the systemic inflammatory environment improve. This represents a rare opportunity where treating one person's condition directly benefits the other's through shared biochemical pathways.

Last updated: April 2026 Wiki synthesized from primary research documents